ESMO 2018 - Grohe poster

Nintedanib* plus docetaxel in routine clinical practice: VARGADO ‒ a German prospective non-interventional study reflecting routine treatment conditions in an evolving NSCLC treatment landscape

Grohé C, Zander I, Lüdtke-Heckenkamp K, Blau W, Krüger S, Franke C, Müller-Huesmann H, Brückl W, Basara N, Ukena D, Lang S, Atz J, Kaiser R

*Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. For the full list of country-specific information please click here. Nintedanib is not approved in other oncology indications.


© 2018 Boehringer Ingelheim International GmbH. All rights reserved.


Last updated: October 2018